Complex medication regimens may be risky and burdensome for community-dwelling older adults suffering from dementia or mild cognitive impairment. Providers should look for ways to reduce ...

Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...

– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...

ARTISTRY-1 trial showed BIC/LEN is effective in maintaining viral suppression in HIV patients previously on complex ART regimens. BIC/LEN offers a single-tablet alternative for patients with drug-drug ...

Best practice calls for discharge planning upon hospital admission. 2 It is clear from the start of the consultation that the patient would not be returning home on the same outpatient ...

Results from ARTISTRY trials will be submitted to regulatory agencies for review. Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study ...

– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 ...

The patient’s antihyperglycemic regimen was revised to insulin detemir 30 units twice daily, insulin aspart 20 units with each meal, and aspart supplemental scale which would give him insulin starting ...